Summary.-The effect of adjuvant immunotherapy with a single neighbourhood injection of 2 mg C. parvum (CP) was investigated in a randomized study involving 43 patients with carcinoma of the cervix uteri, all of whom were treated by radical surgery.. All patients had carcinoma confined to the cervix, the upper part of the vagina or the parametrial region. When the malignancy had spread to the parametrial region, additional postoperative radiotherapy was given. 22 patients received immunotherapy 10 days before surgery, whereas the remaining 21 control patients received no immune stimulation. Only minor side effects of CP were encountered.
THE importance of immunological reactions, especially those involving T lymphocytes and macrophages in the in vivo destruction of tumour cells has been demonstrated (Woodruff, 1980) . This ability of the immune system is of particular interest, since patients suffering from a malignancy show impaired immune reactions. Decreased mitogenic responses (De Cast et al., 1975; Wanebo et al., 1980) , decreased dinitrochlorobenzene (DNCB) skin tests (Pinsky et al., 1974; Elhilali, 1978) , fewer T cells (Wybran & Fudenberg, 1973) and impaired monocyte chemotactic response (Boetcher & Leonard, 1974; Hausman et al., 1975) have all been reported in patients with advanced malignant disease. Factors of low molecular weight derived from the tumour are involved in these functional disturbances (Snijderman et al., 1980) . Corynebacterium parvum (CP) is known to be a potent stimulator of the immune system, and both beneficial (Israel & Edelstein, 1975; Minton et al., 1976; Millar et al., 1981) and detrimental effects (von Blomberg et al., 1980) (Milas et al., 1976) . Therefore the effect of CP might be optimal when used as an adjuvant to radical surgery. It could then interfere with the growth of remote, dormant cancer cells (Woodruff, 1961) or cells metastasizing during the operation (Roberts et al., 1961; Griffith et al., 1973) . Animal experiments have shown beneficial effects of presurgical regional immune therapy in murine lymphosarcoma (Mathe, 1978) .
This report deals with the clinical and immunological effects of a single neighbourhood injection of 2 mg of CP 10 days before radical surgical removal of a cervix carcinoma. Preliminary results show beneficial effects on relapse rates and relapsefree intervals. Enhanced T-cell function could underlie this phenomenon.
PATIENTS AND METHODS
Fifty-eight patients suffering from squamous-cell carcinoma of the uterine cervix preoperatively staged according to the F.I.G.O. classifications as I and II were studied. The mean age was 49 years + 11 (s.d.). All patients were randomly allocated to 2 treatment groups using a computergenerated pseudo-random table, in such a way that an identical distribution of age and preoperative clinical stage were obtained. One of these groups, including 29 patients, received immunotherapy 10 days before radical hysterectomy and lymphadenectomy whereas the other received surgery only. 56 of the 58 hysterectomies were performed by one and the same surgeon (J.G.S.). It was found that 15 patients had more advanced malignancies at operation, with involvement of the pelvic lymph nodes, the pelvic wall, the lower part of the vagina, the urine bladder, the rectum or other distant metastases. But, for our study, we concentrated mainly on the remaining 43 patients whose malignancies at operation were confined to the cervix, the upper part of the vagina and the parametrial region.
Direct postoperative radiotherapy was given when the malignancy affected the parametrial region, the pelvic lymph nodes, the pelvic wall or had grown beyond those stages.
Patients entering the trial had not received any treatment before or had any contraindications for CP treatment.* They were given a clinical follow-up examination every 6 weeks for 6 months, and later every 3 months. Relapse was defined as clinical evidence of local or distant recurrent malignant disease of patients with operable carcinoma. In the group of 15 patients with disseminated disease, relapse w!as defined as a rehospitalization for further treatment of overt malignant disease.
Immunotherapy. Four neighbourhood injections of CP were given 10 days before operation at 4 sites closely surrounding the tumour. The Wellcome strain of CP CN 6134 (Burroughs Wellcome Batch No. Bb 3995) w-as used. A total of 2 mg CP suspended in 2 ml of physiological saline was injected.
Lymphocyte and monocyte count.-The absolute number of lymphocytes and monocytes/ litre blood was calculated from differential blood smears and the absolute number of leucocytes/l blood.
Isolation of blood mononuclear cells.-Blood mononuclear cells were isolated on a FicollIsopaque gradient (Boyum, 1968) using freshly drawn defibrinated blood collected 3 days before CP administration and a few hours before the operation (10 days after immunotherapy).
E and EAC rosettes-.The percentages of E and EAC rosetting cells were estimated in the mononuclear cell suspension by the method described by Zeilemaker et al. (1974) (Mullink et al., 1979 (de Bruine, 1954; Plentl & Friedman, 1971) , viz. 20-25%.
When this is combined with pre-or postoperative radiotherapy the relapse rates are lowered to 10-20% (de Graaff, 1980) . In our clinic, recurrent disease is treated with radiotherapy, which has proved to be as effective as direct pre-or postoperative radiotherapy.
In the group with disseminated disease (Fig. 2) patients treated with CP, whether they had localized or disseminated disease (CP group: 13-0 + 641 vs control group: 6-5 + 3-9 months, Wilcoxon test P < 0 05). Only minor side effects were encountered after the neighbourhood injection of 2 mg of CP. All patients experienced feelings of discomfort, and 85% had a febrile response of up to 39TC. This reaction subsided within 24-36 h. Nausea, vomiting and other severe reactions described after i.v. administration of CP were not observed. Fig. 3 shows the number of E and EAC rosetting cells at the time of operation.
Significantly more E rosettes were found in the immunotherapy group than in the controls; the latter being equal to healthy individuals of matched age and sex. EAC rosettes measured at the same time were similar in all groups of patients and healthy individuals.
The DNCB skin test gave another indication of improved T-cell function after CP treatment (Fig. 4) seen. Specific B-cell stimulation did not occur, as the titre of CP antibodies was unchanged in serum samples taken 10 days after local stimulation.
Before therapy the number of blood monocytes was decreased in carcinoma of cervix patients (Fig. 5) , but the number of macrophage precursors (cells capable of maturing into macrophages) was slightly raised, though this did not reach statistical significance (Wilcoxon test, P= 010). After CP treatment the number of peripheral monocytes dropped significantly to even lower values, as did macrophage precursors. No changes were found in the control group.
DISCUSSION
Our preliminary findings indicate that a relatively small dose of CP given in the neighbourhood of a cervix carcinoma 10 days before radical surgery might slow down the growth of dormant or metastasized cancer cells left behind at operation. A lower relapse rate was observed in patients with localized disease, whereas in more advanced disease a longer relapsefree interval was achieved. A recent study on carcinomas of the oral cavity, pharynx and larynx also indicated that neighbourhood stimulation with CP in addition to surgical treatment decreased the recurrence rates in operable disease (Terz & Kaplan, 1980) . Several other clinical trials are in progress, involving malignant melanoma, bronchus (Ludwig Lung Cancer Group, 1978) and gastric carcinoma (Dykes & Trejdosiewicz, 1978) but no information is yet available on subsequent follow-up. Combinations of surgery with immune stimulants other than CP, such as BCG (Bier et al., 1980; Jansen et al., 1980) , poly A-poly U (Lacour et al., 1980) and interferon (Ikic et al., 1981a,b,c) have also given beneficial results.
CP is known to stimulate local interferon production by lymphocytes, probably NK cells (Kirchner et al., 1.979) . The T-cell responsiveness, as measured by the number of E rosettes and the D.H. reactivity to DCNB were raised in the CP treated group, including both localized and disseminated diseases. This enhanced T-cell responsiveness at the time of operation might counteract the transient T-cell suppression known to occur due to surgical trauma and anaesthetics (Tarpley et al., 1977) . The effects on T lymphocytes are probably induced via stimulation of the monocyte/macrophage series (Scott, 1972) .
In an animal study on lymph-node histological response after local CP stimulation, interactions between lymphocytes and macrophages were evident; 4 to 8 days after stimulation both lymphoblast transformation and mitotic activity were present in the near vicinity of stimulated interdigitating cells, the antigen-handling macrophages of the paracortex (Mignot et et., submitted) . From these observations it is likely that the interval between CP injection and operation should not be less than 6-8 days.
In our group of patients the number of peripheral monocytes dropped after immunotherapy. The percentage of these cells capable of transforming into active macrophages also declined. This disappearance of cells from the blood is known to appear after CP treatment (Thatcher et al., 1979) and lasts for several days. It might indicate sequestration of active cells in other tissue compartments. Histological studies are in progress to see whether there are more macrophages round the tumour at operation. The clinical and immunological data of this trial on cervix carcinoma are in sharp contrast to those of a clinical trial reported on an earlier occasion, involving patients with advanced carcinoma of the bronchus (von Blomberg et al., 1980) . In these patients, CP was administered i.v. in a dose of 7.5 mg/yn2. Severe side effects were encountered, and those treated with CP appeared to have significantly shorter survival. No T-cell stimulation was found, but the titre of CP antibodies was raised. Such a rise of specific antibodies was not found in cervix-carcinoma patients. Possibly a large systemic dose of CP stimulates B cells rather than T cells and, by interference, the production of tumourenhancing antibodies (Moller, 1963) .
Extension of local CP treatment is indicated, and clinical trials are now being carried out involving the combination of paralesional CP and radical surgery of carcinomas of the bronchus, oropharynx and the uterine cervix.
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